BioNotebook: Kite IPO catches strong breeze; plus Endocyte, Merrimack, Aastrom, Nektar, Horizon, Acorda, Ariad
This article was originally published in Scrip
Executive Summary
Kite ends busy IPO week strong; Endocyte, Merck end vintafolide agreement; Merrimack, Sanofi end MM-121 deal; Aastrom strategy includes layoffs; Nektar benefits from Ophthotech/Novartis pact; Horizon secures acquisition debt; and Acorda, Ariad sell notes.